Efficacy and safety of amrubicin‐based regimen used as first‐line for extensive‐disease small‐cell lung cancer: A meta‐analysis of randomized controlled trials

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles